Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;138(Pt 4):1036-45.
doi: 10.1093/brain/awv004. Epub 2015 Feb 15.

Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network

Affiliations

Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network

John M Ringman et al. Brain. 2015 Apr.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Brain. 2015 Dec;138(Pt 12):e401. doi: 10.1093/brain/awv210. Brain. 2015. PMID: 26598496 Free PMC article. No abstract available.

Abstract

Prior studies indicate psychiatric symptoms such as depression, apathy and anxiety are risk factors for or prodromal symptoms of incipient Alzheimer's disease. The study of persons at 50% risk for inheriting autosomal dominant Alzheimer's disease mutations allows characterization of these symptoms before progressive decline in a population destined to develop illness. We sought to characterize early behavioural features in carriers of autosomal dominant Alzheimer's disease mutations. Two hundred and sixty-one persons unaware of their mutation status enrolled in the Dominantly Inherited Alzheimer Network, a study of persons with or at-risk for autosomal dominant Alzheimer's disease, were evaluated with the Neuropsychiatric Inventory-Questionnaire, the 15-item Geriatric Depression Scale and the Clinical Dementia Rating Scale (CDR). Ninety-seven asymptomatic (CDR = 0), 25 mildly symptomatic (CDR = 0.5), and 33 overtly affected (CDR > 0.5) autosomal dominant Alzheimer's disease mutation carriers were compared to 106 non-carriers with regard to frequency of behavioural symptoms on the Neuropsychiatric Inventory-Questionnaire and severity of depressive symptoms on the Geriatric Depression Scale using generalized linear regression models with appropriate distributions and link functions. Results from the adjusted analyses indicated that depressive symptoms on the Neuropsychiatric Inventory-Questionnaire were less common in cognitively asymptomatic mutation carriers than in non-carriers (5% versus 17%, P = 0.014) and the odds of experiencing at least one behavioural sign in cognitively asymptomatic mutation carriers was lower than in non-carriers (odds ratio = 0.50, 95% confidence interval: 0.26-0.98, P = 0.042). Depression (56% versus 17%, P = 0.0003), apathy (40% versus 4%, P < 0.0001), disinhibition (16% versus 2%, P = 0.009), irritability (48% versus 9%, P = 0.0001), sleep changes (28% versus 7%, P = 0.003), and agitation (24% versus 6%, P = 0.008) were more common and the degree of self-rated depression more severe (mean Geriatric Depression Scale score of 2.8 versus 1.4, P = 0.006) in mildly symptomatic mutation carriers relative to non-carriers. Anxiety, appetite changes, delusions, and repetitive motor activity were additionally more common in overtly impaired mutation carriers. Similar to studies of late-onset Alzheimer's disease, we demonstrated increased rates of depression, apathy, and other behavioural symptoms in the mildly symptomatic, prodromal phase of autosomal dominant Alzheimer's disease that increased with disease severity. We did not identify any increased psychopathology in mutation carriers over non-carriers during the presymptomatic stage, suggesting these symptoms result when a threshold of neurodegeneration is reached rather than as life-long qualities. Unexpectedly, we found lower rates of depressive symptoms in cognitively asymptomatic mutation carriers.

Keywords: Alzheimer; behaviour; depression; familial; prodromal.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prevalence of neuropsychiatric symptoms in persons at-risk for autosomal dominant AD mutations. Per cent of non-carriers (white), asymptomatic (CDR = 0) ADAD mutation carriers (light grey), mildly symptomatic (CDR = 0.5) mutation carriers (dark grey), and demented (CDR > 0.05) mutation carriers (hatched columns) with any neuropsychiatric symptoms on the NPI-Q.
Figure 2
Figure 2
Severity of neuropsychiatric symptoms in persons at-risk for autosomal dominant AD mutations. Mean (with SD) plots for (A) Total number of NPI-Q Psychiatric Symptoms, (B) NPI-Q Total Severity Score, and (C) GDS score for non-carriers (white), asymptomatic (CDR = 0) ADAD mutation carriers (light grey), mildly symptomatic (CDR = 0.5) mutation carriers (dark grey), and demented (CDR > 0.05) mutation carriers (hatched columns).

Similar articles

Cited by

  • Neuropsychiatric Symptoms as Predictors of Clinical Course in Neurodegeneration. A Longitudinal Study.
    Santacruz Escudero JM, Beltrán J, Palacios Á, Chimbí CM, Matallana D, Reyes P, Perez-Sola V, Santamaría-García H. Santacruz Escudero JM, et al. Front Aging Neurosci. 2019 Jul 24;11:176. doi: 10.3389/fnagi.2019.00176. eCollection 2019. Front Aging Neurosci. 2019. PMID: 31396074 Free PMC article.
  • Urinary AD7c-NTP Evaluates Cognition Impairment and Differentially Diagnoses AD and MCI.
    Xu MR, Dai RF, Wei QQ, Wang J, Feng YY, Hu Y. Xu MR, et al. Am J Alzheimers Dis Other Demen. 2022 Jan-Dec;37:15333175221115247. doi: 10.1177/15333175221115247. Am J Alzheimers Dis Other Demen. 2022. PMID: 35833655 Free PMC article.
  • Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.
    McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ; Dominantly Inherited Alzheimer Network. McDade E, et al. Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14. Neurology. 2018. PMID: 30217935 Free PMC article.
  • Intermittent Hypoxia Activates N-Methyl-D-Aspartate Receptors to Induce Anxiety Behaviors in a Mouse Model of Sleep-Associated Apnea.
    Fan Y, Chou MC, Liu YC, Liu CK, Chen CH, Chen SL. Fan Y, et al. Mol Neurobiol. 2021 Jul;58(7):3238-3251. doi: 10.1007/s12035-021-02321-0. Epub 2021 Mar 4. Mol Neurobiol. 2021. PMID: 33660202
  • Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
    Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR Jr; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclinical State of AD”; July 23, 2015; Washington DC, USA. Dubois B, et al. Alzheimers Dement. 2016 Mar;12(3):292-323. doi: 10.1016/j.jalz.2016.02.002. Alzheimers Dement. 2016. PMID: 27012484 Free PMC article. Review.

References

    1. Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberger-Gateau P, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol. 2008;64:492–8. - PubMed
    1. Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement Geriatr Cogn Disord. 2008;25:115–26. - PubMed
    1. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795–804. - PMC - PubMed
    1. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–14. - PubMed
    1. Donovan NJ, Amariglio RE, Zoller AS, Rudel RK, Gomez-Isla T, Blacker D, et al. Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry. 2014;22:1642–51. - PMC - PubMed

Publication types